Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expanded ex vivo is a promising therapeutic approach which is currently being investigated clinically as a means of treating various autoimmune diseases and transplant rejection. Despite this, early results have highlighted the need for potent Tregs to yield a substantial clinical advantage. One way to achieve this is to create antigen-specific Tregs which have been shown in pre-clinical animal models to have an increased potency at suppressing undesired immune responses, compared to polyclonal Tregs. This mini review outlines where Treg therapy currently stands and discusses the approaches which may be taken to generate antigen-specific Tregs, including the potential use of chimeric antigen receptors (CARs), for future clinical trials.
Skip Nav Destination
Article navigation
April 2016
-
Cover Image
Cover Image
Endoplasmic reticulumendosome contact sites. This pseudo-colored electron microscopy image shows the formation of inter-organelle membrane contact sites between late endosomes (magenta) and the endoplasmic reticulum (ER; green). This tethering results from the interaction between two ER-anchored proteins (VAP-A and VAP-B) and the late endosomeanchored protein STARD3NL. Mitochondria: brown; nucleus: blue. For further details see pp. 493-498. Image kindly provided by Fabien Alpy. - PDF Icon PDF LinkTable of Contents
Review Article|
April 11 2016
Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?
Dominic Boardman;
Dominic Boardman
*Immunoregulation Laboratory, MRC Centre for Transplantation, Guy's Hospital, King's College London, London SE1 9RT, U.K.
†NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust & King's College London, London SE1 9RT, U.K.
Search for other works by this author on:
John Maher;
John Maher
‡CAR Mechanics Group, Department of Research Oncology, Guy's Hospital, King's College London, London SE1 9RT, U.K.
Search for other works by this author on:
Robert Lechler;
Robert Lechler
*Immunoregulation Laboratory, MRC Centre for Transplantation, Guy's Hospital, King's College London, London SE1 9RT, U.K.
†NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust & King's College London, London SE1 9RT, U.K.
Search for other works by this author on:
Lesley Smyth;
*Immunoregulation Laboratory, MRC Centre for Transplantation, Guy's Hospital, King's College London, London SE1 9RT, U.K.
§School of Health, Sport and Bioscience, University of East London, Stratford Campus, Water Lane, London E15 4LZ, U.K.
1Correspondence may be addressed to either of these authors (email giovanna.lombardi@kcl.ac.uk or lesley.smyth@kcl.ac.uk).
Search for other works by this author on:
Giovanna Lombardi
*Immunoregulation Laboratory, MRC Centre for Transplantation, Guy's Hospital, King's College London, London SE1 9RT, U.K.
†NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust & King's College London, London SE1 9RT, U.K.
1Correspondence may be addressed to either of these authors (email giovanna.lombardi@kcl.ac.uk or lesley.smyth@kcl.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
December 16 2015
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2016 Authors; published by Portland Press Limited
2016
Biochem Soc Trans (2016) 44 (2): 342–348.
Article history
Received:
December 16 2015
Citation
Dominic Boardman, John Maher, Robert Lechler, Lesley Smyth, Giovanna Lombardi; Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?. Biochem Soc Trans 15 April 2016; 44 (2): 342–348. doi: https://doi.org/10.1042/BST20150247
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.